Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group
M. J. Calasanz
Departamento de Citogenética, Universidad de Navarra, Spain,
Search for more papers by this authorM. T. Gómez-Casares
Hospital Ntra Sra. Del Pino de Las Palmas, Spain,
Search for more papers by this authorJ. González-San Miguel
Hospital Insular de Las Palmas, Las Palmas, Spain,
Search for more papers by this authorJ. M. Ribera
Hospital U. Germans Trias i Pujol, Badalona, Spain,
Search for more papers by this authorfor the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group
Hospital Universitario, Salamanca, Spain,
Search for more papers by this authorM. J. Calasanz
Departamento de Citogenética, Universidad de Navarra, Spain,
Search for more papers by this authorM. T. Gómez-Casares
Hospital Ntra Sra. Del Pino de Las Palmas, Spain,
Search for more papers by this authorJ. González-San Miguel
Hospital Insular de Las Palmas, Las Palmas, Spain,
Search for more papers by this authorJ. M. Ribera
Hospital U. Germans Trias i Pujol, Badalona, Spain,
Search for more papers by this authorfor the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group
Hospital Universitario, Salamanca, Spain,
Search for more papers by this authorAbstract
Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)-form (50%), eight variable (V)-form (5%) and 76 short (S)-form (45%). The V-form and S-form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 109/l (P < 0·05). The S-form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0·005) and CD34 expression (P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3-year disease-free survival was lower for V-form cases than it was for L- and S-form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V-form and S-form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V-form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.
References
- Biondi, A., Rambaldi, A., Pandolfi, P.P., Rossi, V., Giudici, G., Alcalay, M., Lo Coco, F., Diverio, D., Pogliani, E.M., Lanzi, E.M., Mandelli, F., Masera, G., Barbui, T., Pelicci, P.G. (1992) Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood, 80, 492–497.
- Chillón, M.C., González, M., García-Sanz, R., Balanzategui, A., González, D., López-Pérez, R., Mateos, M.V., Alaejos, I., Rayón, M.C., Arbeteta, J., Hernández, J.M., Orfao, A., San Miguel, J.F. (2000) Two new 3′ PML breakpoints in t(15;17) (q22;q21) positive acute promyelocytic leukemia (APL). Genes Chromosomes and Cancer, 27, 35–43.DOI: 10.1002/(sici)1098-2264(200001)27:1<35::aid-gcc5>3.3.co;2-n
- Fukutani, H., Naoe, T., Ohno, R., Yoshida, H., Miyawaki, S., Shimazaki, C., Miyake, T., Nakayama, Y., Kobayashi, H., Goto, S., Takeshita, A., Kobayashi, S., Kato, Y., Shiraishi, K., Sasadea, M., Ontake, S., Murakami, H., Kobayashi, M., Endo, N., Shindo, H., Matsushita,, Hasegawa, S., Tsuji, K., Ueda, Y., Tominaga, N., Furuya, H., Inoue, Y., Takeuchi, J., Morishita, H., Lida, H. (1995) Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia, 9, 1478–1482.
- Gallagher, R.E., Li, Y.P., Rao, S., Paietta, E., Andersen, J., Etkind, P., Bennett, J.M., Tallman, M.S., Wiernik, P.H. (1995) Characterization of acute promyelocytic leukemia with PML-RARα break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood, 86, 1540–1547.
- Gallagher, R.E., Willman, C.L., Slack, J.L., Andersen, J.W., Li, Y.-P., Viswanatha, D., Bloomfield, C.D., Appelbaum, F.R., Schiffer, C.A., Tallman, M.S., Wiernik, P.H. (1997) Association of PML/RARα fusion mRNA type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood, 106, 591–613.
- Grimwade, D. (1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 94, 557–573.
- Guglielmi, C., Martelli, M.P., Diverio, D., Fenu, S., Vegna, M.L., Cantù-Rajnoldi, A., Biondi, A., Cocito, M.G., Del Vecchio, L., Tabilio, A., Avvisati, G., Basso, G., Lo Coco, F. (1998) Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. British Journal of Haematology, 102, 1035–1041.DOI: 10.1046/j.1365-2141.1998.00871.x
- Huang, W., Sun, G.L., Li, X.S., Cao, Q., Lu, Y., Jang, G.S., Zhang, F.Q., Chai, J.R., Wang Z., Waxman, S., Chen, Z., Chen, S.J. (1993) Acute promyelocytic leukemia: clinical relevance of two major PML/RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood, 82, 1264–1269.
- Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., Broccia, G., Cerri, R., Falda, M., Fioritoni, G., Leoni, F., Liso, V., Petti, M.C., Rodeghiero, F., Saglio, G., Vegna, M.L., Visani, G., Jehn, V., Willemze, R., Muus, P., Pelicci, P.G., Biondi, A., Lo Coco, F. (1997) Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood, 90, 1014–1021.
- Sanz, M.A., Martín, G., Rayón, C., Esteve, J., González, M., Díaz-Mediavilla, J., Bolufer, P., Barragán, E., Terol, M.J., González, J.D., Colomer, D., Chillón, M.C., Rivas, C., Gómez, T., Ribera, J.M., Borstein, R., Román, J., Calasanz, M.J., Arias, J., Alvarez, C., Ramos, F., Debén, G. (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood, 94, 3015–3021.
- Slack, J.L., Willman, C.L., Andersen, J.W., Li, Y.-P., Viswanatha, D.S., Bloomfield, C.D., Tallman, M.S., Gallagher, R.E. (2000) Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARα isoform: results from Intergroup protocol 0129. Blood, 95, 398–403.
- Van Dongen, J.J.M., Macintyre, E.A., Gabert, J.A., Delabesse, E., Rossi, V., Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., Parreira, A., Gameiro, P., González, M., Malec, M., Langerak, A.W., San Miguel, J.F., Biondi, A. (1999) Standardized RT–PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia, 13, 1901–1928.
Citing Literature
